Jarman Julian We, Hunter Tina D, Hussain Wajid, March Jamie L, Wong Tom, Markides Vias
Cardiology & Electrophysiology, Heart Rhythm Center, NIHR Cardiovascular Research Unit, The Royal Brompton Hospital, and National Heart and Lung Institute, Imperial College London, London, UK.
Health Outcomes Research, CTI Clinical Trial & Consulting Services Inc., Cincinnati, OH.
Pragmat Obs Res. 2017 May 29;8:107-118. doi: 10.2147/POR.S134781. eCollection 2017.
We sought to determine whether catheter ablation of atrial fibrillation (AF) is associated with reduced occurrence of ischemic cerebrovascular events.
Using routinely collected hospital data, ablation patients were matched to two control cohorts via direct and propensity score matching. A total of 4,991 ablation patients were matched 1:1 to general AF controls with no ablation, and 5,407 ablation patients were similarly matched to controls who underwent cardioversion. Yearly rates of ischemic stroke or transient ischemic attack (stroke/TIA) before and after an index date were compared between cohorts. Index date was defined as the first ablation, the first cardioversion, or the second AF event in the general AF cohort. Matched populations had very similar demographic and comorbidity profiles, including nearly identical CHADS-VASc risk distribution (-values 0.6948 and 0.8152 vs general AF and cardioversion cohorts). Statistical models of stroke/TIA risk in the preindex period showed no difference in annual event rates between cohorts (mean±standard error 0.30% ± 0.08% ablation vs 0.28% ± 0.07% general AF, =0.8292; 0.37% ± 0.09% ablation vs 0.42% ± 0.08% cardioversion, =0.5198). Postindex models showed significantly lower annual rates of stroke/TIA in ablation patients compared with each control group over 5 years (0.64% ± 0.11% ablation vs 1.84% ± 0.23% general AF, <0.0001; 0.82% ± 0.15% ablation vs 1.37% ± 0.18% cardioversion, =0.0222).
Matching resulted in cohorts having the same baseline risks and rates of ischemic cerebrovascular events. After the index date, there were significantly lower yearly event rates in the ablation cohort. These results suggest the divergence in outcome rates stems from variance in the treatment pathways beginning at the index date.
我们旨在确定心房颤动(AF)导管消融术是否与缺血性脑血管事件发生率降低相关。
利用常规收集的医院数据,通过直接匹配和倾向评分匹配将消融患者与两个对照组进行匹配。总共4991例消融患者与未进行消融的一般房颤对照组1:1匹配,5407例消融患者同样与接受心脏复律的对照组匹配。比较各队列在索引日期前后缺血性卒中或短暂性脑缺血发作(卒中/TIA)的年发生率。索引日期定义为首次消融、首次心脏复律或一般房颤队列中的第二次房颤事件。匹配人群具有非常相似的人口统计学和合并症特征,包括几乎相同的CHADS-VASc风险分布(与一般房颤和心脏复律队列相比,P值分别为0.6948和0.8152)。索引前期卒中/TIA风险的统计模型显示各队列之间年事件发生率无差异(消融组平均±标准误0.30%±0.08% vs一般房颤组0.28%±0.07%,P = 0.8292;消融组0.37%±0.09% vs心脏复律组0.42%±0.08%,P = 0.5198)。索引后期模型显示,在5年期间,消融患者的卒中/TIA年发生率显著低于各对照组(消融组0.64%±0.11% vs一般房颤组1.84%±0.23%,P < 0.0001;消融组0.82%±0.15% vs心脏复律组1.37%±0.18%,P = 0.0222)。
匹配使得各队列具有相同的基线风险和缺血性脑血管事件发生率。索引日期之后,消融队列的年事件发生率显著降低。这些结果表明,结局率的差异源于索引日期开始的治疗路径差异。